Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lily Tang
Institution:
Nektar Therapeutics (United States)
Observed institution:
Nektar Therapeutics (United States)
ORCID:
0009-0004-9157-7223
Observed ORCID:
0009-0004-9157-7223
OpenAlex ID:
A5085070996
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
2024
·
Nizar M. Tannir
, Maria Nirvana Formiga
, et al.
·
Journal of Clinical Oncology
·
40
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
2022
·
Nizar M Tannir
, Daniel C Cho
, et al.
·
Journal for ImmunoTherapy of Cancer
·
28
PDF
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
2022
·
Arlene O. Siefker-Radtke
, Daniel C. Cho
, et al.
·
European Urology
·
20
Show more works
View as search
Works count:
3
Citation count:
88
H-index:
3
I10-index:
3
Year
Topic
Type
